Victory Capital Management
AZN icon

Victory Capital Management’s AstraZeneca AZN Stock Holding History

Victory Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.76M Sell
11,255
-153,248
-93% -$29.5M ﹤0.01% 1643
2025
Q4 		$30.2M Sell
164,503
-22,599
-12% -$3.96M 0.02% 727
2025
Q3 		$28.7M Sell
187,102
-5,630
-3% -$852K 0.02% 766
2025
Q2 		$26.9M Sell
192,732
-26,365
-12% -$3.7M 0.02% 775
2025
Q1 		$32.2M Buy
219,097
+17,062
+8% +$2.47M 0.03% 628
2024
Q4 		$26.5M Buy
202,035
+70,758
+54% +$9.91M 0.03% 730
2024
Q3 		$20.5M Sell
131,277
-949
-0.7% -$153K 0.02% 839
2024
Q2 		$20.6M Sell
132,226
-620
-0.5% -$93.3K 0.02% 802
2024
Q1 		$18M Sell
132,846
-4,713
-3% -$624K 0.02% 853
2023
Q4 		$18.5M Buy
137,559
+262
+0.2% +$34.1K 0.02% 806
2023
Q3 		$18.6M Buy
137,297
+25,844
+23% +$3.53M 0.02% 783
2023
Q2 		$16M Sell
111,453
-6,395
-5% -$941K 0.02% 860
2023
Q1 		$16.4M Buy
117,848
+18,156
+18% +$2.44M 0.02% 861
2022
Q4 		$13.5M Sell
99,692
-4,831
-5% -$606K 0.02% 922
2022
Q3 		$11.5M Buy
104,523
+17,284
+20% +$2.19M 0.01% 1022
2022
Q2 		$11.5M Buy
87,239
+709
+0.8% +$93K 0.01% 1018
2022
Q1 		$11.5M Buy
86,530
+46,404
+116% +$5.56M 0.01% 1068
2021
Q4 		$4.67M Buy
40,126
+20,044
+100% +$2.36M ﹤0.01% 1343
2021
Q3 		$2.41M Sell
20,082
-2,899
-13% -$337K ﹤0.01% 1545
2021
Q2 		$2.75M Sell
22,981
-7,310
-24% -$802K ﹤0.01% 1539
2021
Q1 		$3.01M Buy
30,291
+1,448
+5% +$146K ﹤0.01% 1521
2020
Q4 		$2.88M Buy
+28,843
New +$3.06M ﹤0.01% 1394
2019
Q3 		– Sell
-206,272
Closed -$17M – 3764
2019
Q2 		$17M Buy
206,272
+2,185
+1% +$171K 0.03% 656
2019
Q1 		$16.5M Hold
204,087
– – 0.04% 611
2018
Q4 		$15.5M Buy
+204,087
New +$15.9M 0.04% 618

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Victory Capital Management's AZN Position: Q1 2026 in Review

Victory Capital Management reduced its AstraZeneca (AZN) stake by 93% in Q1 2026, selling an estimated $29.5M and leaving 11,255 shares worth $1.76M. The position accounts for ﹤0.01% of the portfolio, ranked #1643.

Victory Capital Management first reported a position in AZN in Q4 2018 and has held it in 25 quarters since. The position peaked at $32.2M in Q1 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Victory Capital Management held 11,255 shares of AstraZeneca worth $1.76M as of Q1 2026.
  • Victory Capital Management sold 153,248 AstraZeneca shares in Q1 2026, an estimated $29.5M.
  • AstraZeneca made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #1643 holding.
  • Victory Capital Management first reported a position in AstraZeneca in Q4 2018 and has held it in 25 quarters since.
  • Victory Capital Management's AstraZeneca position peaked at $32.2M in Q1 2025.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.